Index

Abelson, J., 254–255
Academia Platonica (Neoplatonic Florentine Academy), 218
Academy of Medical Sciences (AMS, UK), 358–359
goals and mission of, 3–5
access to healthcare
benefit sharing and, 154–156
orphan drug research and, 62
solidarity and, 59–61
accountability
governance and, 123–124
institutional decision-making and, 211
medical device failure and, 163–164
non-traditional medicine and, 299
actor-networks
Big Data research and, 257–259
global health emergency guidelines and, 316–317
adaptive governance principles
Big Data research and, 257–265
evolution of, 257–259
structures and processes in, 263–265
visibility, 264–265
risks of, 380–381
adaptivity, in health research governance, 259–260
Addgene company, 142–144
Additional Protocol (2005), 105–106
add-on services in reproductive medicine
ethical issues with, 375–377
patient choice dynamic in, 380
regulation of, 577–579
risks of, 380–381
Advanced Therapies
Argentinian regulation of, 324–333
regenerative medicine and, 324
advertising of innovative intervention, oversight of, 292–295
Advisory Commission on Regenerative Medicine and Cellular Therapies (Argentina), 325–326
advocacy committees
adaptive governance and, 263–265
Advisory Commission on Regenerative Medicine and Cellular Therapies (Argentina), 325–326
in bioethics, 220–222
Bioethics Advisory Body, 284–285
future of health research regulation and, 222–224
health policy advice and, 215–216
advocates, public engagement with, 117
affected public
classification of, 117
data-intensive health research and, 118–119
AFIRRM oversight model
Big Data research and, 259–260
future challenges for, 265
implementation of, 260–263
agency, automated healthcare regulation and, 268–269,
273
aggregated data, individual discrimination and
stigmatisation and, 242
aggregative theories, public interest and, 240
Aitken, Mhairi, 14, 70–71, 112–129
Alder Hey organ retention scandal, 212–213
Aldrich, Philip, 270
Allen, A. L., 75
All of Us initiative, 103–104
All Party Parliamentary Group on Surgical Mesh Implants, 182–185
alternative medicine
history and evolution of, 296–298
research regulation of, 296–305
uncertainty of knowledges and practices and, 303–304
21 in vitro add-on, 375–377
Alhusser, L., 23–25
animal research
embryo research and, 356–364
human material in animals and, 358–359
interpecies research and, 356–364
in neuroscience, 310–312
regulation and oversight of, 379–362
shifting regulatory boundaries in, 360–363
vulnerability issues in regulation of, 363–364
Animals Containing Human Material (Academy of Medical Sciences), 358–359
Annas, George, 352
Ansell, C., 124–127, 128–129
anticipatory knowledge
emerging science and technology oversight and, 397–399
in global health emergency research, 322–323
participatory health governance and, 285–286
anti-science politics
health policy formation and, 216–218
health research regulation and, 222
traditional and non-conventional medicine and, 301–302
Argentina
agricultural strength and health fragmentation in, 324–325
cell therapy research governance in, 325–326
construction of research governance in, 328–329
current health legal/regulatory framework in, 330–331
health research regulation in, 334–331
Arnstein, S. R., 114, 116
ArthritisPower network, 126–127
artificial intelligence (AI)
best practices guidelines and, 175
co-dependent human-technology embodiment and, 383–384
continuous learning, research-therapy divide and, 27–29
existence conditions and, 27a as medical device, 277–286
regulatory responsibility and, 271–274
voluntariness in, 107–108
assisted reproduction, human germline research and, 348–350
Association of University Technology Managers, 142–143
Australia
cloning research in, 347–348
evidence-informed health policy in, 216–218
Australian Academy of Learned Societies, 220
authority. See governance
autologous mesenchymal stem cell case study, clinical innovation oversight and, 290–292
automated healthcare regulation
balance of interests in, 267–268
moral development and agency and, 273–274
regulatory responsibility and, 271–274
self-development and agency issues and, 273
stewardship responsibilities in, 269–269
autonomy
artificial intelligence and, 271
disclosure of research findings and, 231–234
health research ethics guidelines, 27–29
health research regulation and, 13–15
individualistic conceptions of, 29–30
informed consent and, 104–105, 108–109
non-invasive prenatal testing and, 267–268
privacy and, 246
relational conceptions of, 27–29
availability heuristic, risk-benefit analysis and, 134–135
Awesan initiative, 103-104
Baier, A., 84–85
balance of interests
automated healthcare regulation and, 272
health research regulation and, 268
Ballantyne, A., 23–24
Barbarza, E., 123–124
Barber Surgeons of Edinburgh, 228
Barsdorf, Nicola, 51–52
Bea, Sara, 356–364
Beauchamp, T. L., 59, 169–170
beliefs, facts and, health policy and, 217
Belmont Report (1979), 7–8
autonomy guidelines in, 27–29
social values, 40–47
vulnerability guidelines in, 17–18, 33
beneficence
autonomy guidelines and, 27–29
informed consent and, 104–105
proportionality and, 39
benefit analysis
risk-benefit analysis and, 112–114
social value and, 53–54
benefit evaluation, social value and, 54
benefits, defined, 149–153
benefit sharing
challenges to, 154–156
common heritage argument for, 150–153
data access agreements and, 191
descriptive argument for, 150–151
governance frameworks for, 151–153
health research regulation and, 148–157
history and rationale for, 149–151
procedures for, 153–154
benefit treatment, social value and, 54
Bennet, C. J., 241–243
Bennett, Alan, 145–146
Beresford, P., 121–122
Berger, M., 251–252
best practices
displacement of traditional medicine in, 290–301
examples, 192–195
health research regulation, 173–175
in vitro fertilisation and, 174
Big Data research. See also data-driven research
adaptive governance in regulation of, 257–259
analytical techniques in, 257–259
deliberative participatory practices and, 125–126
effective governance of, 260–265
participatory governance of research and, 121
patient and public involvement in, 121–123
regulatory scholarship on, 257–259
structures and processes in, 263–265
systemic oversight framework for, 259–260
uncertainty in, 262–265
voluntariness in, 107–108
biohacks
disclosure of research findings and role of, 233
regulation of, 6–7
BioBricks Foundation, 142–143
bioethics
advisory committees, 220–222, 284–285
French law on, 264
medical device failure and, 162–165
Bioethics (journal), social value debate in, 51–52
biosecurity regulations, in Argentina, 324–325
blaming, medical device failure and, 163–164
Index

patient and public involvement and, 123–125
in vitro fertilisation and, 375–377
consumers, public engagement with, 117
context in adaptive governance, 262
in global health emergency guidelines, 316–317
health research regulation and role of, 275–276
in human gene research, 348–350
of institutions, 207–208
proportionality and, 17–18
rule-based and practice-based health regulation and, 172–173
Contreras, Jorge, 140–142
controlled access, data-driven research, 190–191
Convention for the Protection of Individuals with regard to Automatic Processing of Personal Data (Council of Europe), 243–245
Convention on Biological Diversity (CBD) (1992), 149
cooperative practice, human germline research, 350–352
cooperative tool for capacity building, benefit sharing and, 153
coop-option, participatory governance and, 127
costs of health research, solidarity on, 59–61
Council for International Organizations of Medical Sciences (CIOMS), 88–90
benefit sharing guidelines and, 151–153
global health emergency guidelines and, 316–317, 320–322
guidelines, 47–49
health practices guidelines, 173–175
informed consent and, 105–106, 200–201
reasonable availability model of, 152–153
risk-benefit analysis guidelines, 117
social value in health research regulation and, 46–47, 49–51, 199–200
on third-party risks, 170–172
Council of Canadian Academies (CCA), 219–220
Council of Europe data protection law and, 247–248
genetics research regulation and, 340–341
informed consent and, 105–106
Council on Health Research for Development (COHRED), 85–86
COVID-19 pandemic health practices guidelines and, 173–175
research exceptionalisms and, 318–320
credibility tactics, participatory governance and, 127
Crick, Bernard, 96
criminal law
genetics research regulation and, 337–340
human embryo research and, 358–359
physical integrity and identity in, 385–386
cross research global health emergency guidelines and, 316–317
human gene editing regulation and, 335–336
risk assessment in, 199–200
social value of, 317–318
criticism, of research ethics, 200–201
cross-border data sharing, in Big Data research, 123

404

collective interests
health research regulation and, 7, 14
public expertise mobilisation and, 253–255
commercialisation of research
benefit sharing and, 153–156
data access and, 109–115
group vulnerability and, 97
health research regulation and, 7
common good
automated health regulation and, 268–269
privacy and, 75
common heritage argument for benefit sharing, 130–132
common interest theory
group privacy and, 241–243
public interest and, 240–241
Common Rule. See Federal Policy for the Protection of Human Subjects (Common Rule, US)
common value theory, 240–242
commissarism approach
automated health regulation and, 268–269
benefit sharing, 153–154
global health emergencies and, 319–320
informed consent and, 108–109
institutional decision-making and, 210
risk-benefit analysis and, 118
community advisory boards, participatory health systems governance and, 125–126
community values. See social value
Compagnie du Gas Sèvrais, 218
comparative effectiveness research, minimal risk principle and, 199–200
competency
autonomy and, 31
informed consent and, 106
competition, patent regulation and, 140–141
complementarity, governance structures and, 264
complementary and alternative medicine (CAM). See alternative medicine
component analysis, risk-benefit analysis using, 137–138
confidentiality in Big Data research, 123
duty of confidence and, 245–246
in neuroscience research, 508
privacy and, 79
public interest guidelines and, 67–70
Confidentiality Advisory Group (CAG) (HRA, UK), 67–70, 212–213
Confronting the Liminal Spaces of Health Research Regulation project, 3
consent. See informed consent
consent or anonymise regulation model, 4
consent to contact policies, 201–202
consultation, public engagement through, 115–116
consumer approach
autologous mesenchymal stem cell case, 290–292
clinical innovation and intervention and, 289
innovation oversight and limits of, 292–295
medical device regulation and, 386–389
misinformation about reproductive medicine and, 379
non-traditional medicine and, 299
cultural issues
disclosure of research findings and, 233–234
interspecies biomedical research regulations and, 312–313
medical device failure and, 165–164
privacy and, 241–243
culturally significant information, protection of, 242n.23
Cunningham-Burley, Sarah, 112–113
Curran, William, 181–182
cyborg perspective, enhancement innovations and, 585
D’Amour, D., 83
data access agreements, 191
centralised access, genotype/phenotype database, 193
challenges and future directions, 195–196
governance of, 197–198
harmonisation of policies and processes in, 196
independent, interdisciplinary access, 193–194
multi-study access, EGA, 192
oversight coordination, 195–196
producers’ rights and interests and, 194
resources, effectiveness and efficiency in, 193
tiered access, International Cancer Genome Consortium/c2K initiative, 193
transparency and reflexive governance, 194–195
Data Access Committees (DACs), 188–189
adaptive governance and, 263–265
controlled vs. open access data and, 190–191
monitoring of data use and, 191–192
multi-study access, EGA, 192
oversight coordination, 195–196
resources, effectiveness and efficiency in, 193
data-driven research. See also Big Data research
automated healthcare regulation and, 270
controlled vs. open access data, 190–191
current and future trends in, 198–199
disclosure of research findings and, 229–234
confidence and privacy of, 245–246
EGA and, 192
group privacy protections in, 247–248
health research regulation and, 7–8
informed consent and, 103–104
integrity and ethics protections, 188–189
monitoring of data use and, 191–192
in neurosciences, 308
privacy rights and, 75–77
producer rights and interests in, 189–190
public engagement in, 116, 118–119
public perceptions of, 217
relationality in, 59–61
rules-based vs. practice-based approaches in regulation of, 170–171
subject rights and, 188–189
trustworthiness of research governance and, 248–249
value and social values in, 394–396
Data Protection Act 2018 (DPA, UK)
consent of, 69
HRR community lobbying and, 71–72
neuroscience research and, 310–312
research governance and, 167–169
Data Protection Regulation 2016/679 (GDPR) (EU), 75–77
data sharing
governance frameworks for, 187–188
informed consent and, 105–106
in neuroscience research, 308
participatory learning in regulatory governance and, 254–255
privacy protection and, 73–74
public engagement and, 116
trustworthiness of, 87–89
Datta, A. K., 176
Davidson, S., 115–116
Dawson, A., 91, 97
decision-making
accountability and risk aversion issues in, 211
central objectives in, 228–230
disclosure of research findings for purposes of, 231
in global crisis emergencies, 317–318
health research regulation and, 99–103
inclusion and equality in, 127
institutional influences on, 205–214
institutional structure and composition and, 209–211
path dependencies and historical influences in, 212–213
privacy in, 75–77
public interest and, 240–241
public vs. private duties in, 211
social value and, 54
Declaration of Alma Ata (1978), 289–291
Declaration of Ichang Mai, 300
Declaration of Helsinki
autonomy guidelines in, 27–29
benefit sharing in, 151–152
group access to research participation in, 172–173
informed consent in, 105–107
post-trial obligations in, 152–153
social value in, 46–47, 52–53
vulnerability guidelines in, 18, 90–91
Declaration of Taipei on Ethical Considerations regarding Health Databases and Biobanks, 103–104
De Cleen, B., 251–252
deep learning, medical devices and, 251
default consent, 107–108
deficit model of public understanding, 112–113
Degenel, C., 117
deliberative practices
diversity theory and, 252–253
participatory health governance and, 124–126
public expertise mobilisation and, 248–256
Delphi policy study, 397–399
democratic approach, patient and public involvement and, 121–123
De Novo premarket review process (FDA), 278–281
deontological theory, privacy and, 78–79
descriptive argument for benefit sharing, 150–151
diabetic retinopathy, software as medical device for diagnosis of, 278–281
dialogue, public engagement and role of, 189–190
Index

Epshteyn, S., 127
equality
diversity theory and, 252–253
non-invasive prenatal testing and, 267–268
Ethical and Policy Issues in International Research
(National Bioethics Advisory Commission), 151–152
ethical issues in health research
autonomy guidelines, 27–29
benefit sharing and, 151–153
in Big Data research, 123
bioethics advisory committees, 220–222
chimeric research oversight and guidelines and, 559–560
data protections and, 188–189
disclosure of research findings and, 229–231
enhancement innovations and, 183
ethical approvals process and, 507–509
ethical licensing, 145–146
evaluation of regulatory changes and, 202–203
exemption for types of research, 200–201
future directions in, 182–185
gene-editing and, 267–268
global health emergencies and, 315–323
health policy formation and, 217–218
human-technology embodiment and, 584–586
incidental findings and, 229–231, 309–310
ethical licensing, 145–146
evaluation of regulatory changes and, 202–203
exemption for types of research, 200–201
future directions in, 182–185

epistemology and, 92–93
randomized controlled clinical trials in, 112–114
unregistered interventions in, 310

EC Regulation 14/2000, 62–63
Editas company, 145–146
Edwards, Robert, 373–374
effectiveness of medical devices, marginalised focus on, 162–165
efficacy
social value and estimation of, 53–54
in traditional medicine, research on, 299–301
egalitarian diversity and inclusiveness, 252–253
Egelie, Knut, 143–144
Eisenberg, Rebecca, 141
electronic signatures, informed consent and, 110
Emanuel, E., 46–47, 180–181
empowerment
participatory health governance and, 144–145
public engagement and, 116
enforceable norms, solidarity and, 58–59
engagement, proportionality and, 144–145
enhancement innovations, development of, 583–584
epistemological injustices, relational autonomy and, 33–36
epistemic integration, medical device failure and, 165–166
Index

EU Directive 2001/20/EC, 200–201
EU Directive 2004/24/EC, 300–301
EU Regulation 2017/745, 382–383
European health research regulation in, 1
European Convention on Human Rights (ECHR), 74–75, 245–246
European Court of Human Rights, 75, 245–246
European Directive on Traditional Herbal Medicine Products (THMPD), 297–298
European General Data Protection Regulation, 105–106
European Genome-phenome Archive (EGA), 192
European Group on Ethics in Science and New Technologies to the European Commission, 151–152
European Medicines Agency (EMA)
advanced therapies regulation and, 334
Argentinian regulatory harmonisation with, 328–329
regulatory science and, 394
reproductive medicine add-on services regulation and, 577–579
European Open Science Cloud (EOSC), 7–8
European Union (EU)
Data Protection Regulation 2016/679 (GDPR), 75–77
data protection regulation in, 67–70, 167–169, 171, 243–245
device development by, 160–161
medical device regulation in, 386–388
regulatory regime in, 14, 46


evidence-based healthcare. See also non-evidence-based medicine
Big Data research and, 257–259

economics of clinical guidelines and, 301–302
health policy formation and, 216–218
learned and academic societies’ evaluation of, 220
norms of evidence and, 303–304
placebo controls and, 258–259
risk-benefit analysis and ethics review and, 117–118
traditional and alternative medicines and, 296–305

excessive risk, risk-benefit analysis and, 136–137
exclusion criteria
proportionality and, 40
in vulnerability research, 20–22
existence conditions, automated healthcare regulation and, 272

expectations in health research
Argentinian regulation of, 327–328
failure and, 159–162
neuroscience and, 308–309
reproductive immunology mythology and, 370–377
reproductive medicine and role of, 374

experimental interventions
global health emergencies and, 318–320
vulnerability and, 92–93

experts and expertise
evidence-based medicine and, 298–299
future of health research regulation and, 222–224
health policy advice and, 215–224
learned and academic societies, 218–220

mobility in health research regulation of, 248–256
representation and inclusiveness issues in, 251–253
reproducibility, artificial intelligence and, 271

exploitation
group vulnerability to, 93–95
vulnerability in health research and, 91–92

externalist perspective, relational autonomy and, 31
external validity, in RCTs, 133

facilitative leadership
participatory governance and, 128–129
proportionality and, 42–43

failure in health research
expectations and, 159–162

history of, 158
legal interpretations and constructions of, 161–162
risk assessment and prevention, 158–166

systemic causes of harm and, 162–165

values failure, 195

failure of care data, public interest in HRR and, 69–70

fair benefits model, benefit sharing and, 153

Fairmichael, F., 395

fairness
artificial intelligence and, 271

non-invasive prenatal testing and, 267–268

fair participation, global health emergency research and, 298–300

Federal Advisory Committee Act (US), 220–221


Federal Regulations on Research With Human Participants (US), 150–152

federal science advisor, 222–223

feedback policies
disclosure of research findings and, 231–234

ethical responsibilities in, 226–228

participants’ interest and, 214–215

Fenney, Oliver, 143–144

fertility medicine. See in vitro fertilisation, reproductive medicine

fictional man paradigm, public interest litigation and, 69

final cause/objective, of institutional decision-making body, 208–209

Financial Services Authority (FSA, UK), 257–259

Fineman, M. A., 19

first-order proportionality, defined, 37–38

Fish, Stanley, 210

510(k) pathway, medical device trials, 279–281

Flear, Mark, 158–166

flexibility, in health research governance, 259–260

Foley, T., 395

follow-on research, non-exclusive research tool licensing and, 144–145

Food, Drug and Cosmetic Act (US), medical device definition in, 278–281
Index

disclosure of research findings and, 231–234
failure of care data, 69–70
regulatory regimes vs., 6
research and, 6
research-therapy divide in technology governance and,
277–286
resistance to participatory governance in, 125
health research, value-driving paradigm for,
294–296
Health Research Authority (HRA) (UK), 205
Confidentiality Advisory Group (CAG), 212–213
institutional overview of, 208–209
Proportionate Review Service, 182–184
public interest guidelines, 67–70
health research regulation
Argentinian advanced therapies research, 324–331
automated healthcare, 266–274
benefit sharing and, 148–157
best practices and, 177–175
clinical innovation and barrier of, 287–290
countervailing trends in, 201–202
current and future trends in, 197–203
design innovations in, 182–184
disclosure of findings, protocols for, 229–238
evaluation of changes to, 202–203
expert and advisory advice in, 215–224, 248–256
failure in, 158–166
future issues for, 222–224
human embryo research, 265–272
human gene editing, 335–345
human germline research, 350–352
institutional influence in, 205–214
interspecies research and, 350–356
key concepts in, 13–15
learned and academic societies’ influence on, 218–220
medical devices, 277–286, 382–390
in neuroscience research, 304
non-evidence based reproductive medicine and,
373–381
patent regulation, 159–167
policy advice sources in, 215–224
privacy and public interest in, 239–247
problems and issues with, 1–3
process simplification and harmonisation and, 200–201
public interest appeals in, 66–67
recent changes in, 3–5
responsible regulation development, 333–334
review as regulatory process and, 178–180
risk-benefit analysis in, 130–138
rule, principles and guidance-based initiatives, 167–176
shared practices in, 59–61
software as medical device and, 277–286
solidarity in, 56–64
supplementary guidance and, 173–175
traditional and non-conventional medicines, 296–305
visibility of, 264–265
health research systems
informed consent and evolution of, 103–104
participatory governance in, 123–126
health systems research, social value in, 51–52
He Jiankui, 345–346, 351, 354–355
Index

Held, V. P., 240
Heller, Michael, 141
hematopoietic progenitor cells (HPC), Argentinian regulation of research on, 326–328
Hendy, Tereza, 287–295
Heneghan, Carl J., 160–161
High Level Expert Group (HLEG), 7–8
Hilgartner, Stephen, 219
Hinterberger, Amy, 356–364
Hirsch Index, 47–49
historical influences, institutional decision-making and, 212–213
Ho, Calvin W. L., 277–286
Hodgen, G. M., 207–208
Hoffmann (Lord), 245–246
homeopathic practices, guidelines for, 301–302
homogeneity of institutions, 213
Horizon Programme, 342
human assemblage ideology, human-technology embodiment and, 354–356
human-centric governance, automated healthcare regulation and, 272
human challenge trials, debate over, 318–320
human embryo research
admixed embryos, 358–359
evolution of regulatory framework for, 366–368
14-day rule and, 361–366
interspecies research and, 356–358
regulation of research on, 365–372
revising 14-day rule in, 370–372
special status principle in, 367–368
terminology and definitions of, 347–348
threshold of humanity principle and, 370–372
Human Fertilisation and Embryology Act and Authority, HFEA (1990, UK)
Code of Practice, 378–379
data protection regulation in, 171
human embryo research and, 358–359, 365–368
human germline research and, 346–350
reproductive immunology warning and, 376–377
reproductive medicine add-on services and, 378–379
revisions to, 368–370
in vitro fertilisation licensing and, 374
human gene editing
harmonisation of regulations on, 340–344
international health policy frameworks and, 340–344
moral concerns over, 356–358
national policy frameworks for, 337–340
normative regulatory systems for, 335–344
slippery slope ideology and, 369–370
Human Genome Organization (HUGO), 149–151
Human Genome Project, 103–104
open access and, 190–191
human germline research
context in, 348–350
ethical debates over, 344–355
future research challenges in, 354–355
global regulation and scientific justice, 352–353
harmonization of regulations on, 340–345
international health policy frameworks and, 340–341
national policy frameworks for, 337–340
normative regulatory framework for, 338–341
overview, 345–346
regulation, responsibility and cooperative research in, 350–352
terminology and definitions, 346–348
humanitarian crises
health care regulation and, 199
research ethics in, 315–325
social value of research in, 317–318
humanity, threshold of
enhancement innovations and, 383
human embryo research and, 370–372
Human Medicines Regulations 2012 (UK), 377–379
human rights
automated healthcare regulation and, 270
disclosure of research findings and, 233–234
duty of confidence and, 346
genetics research regulation and, 340–341
human embryo research and, 366–368
identity as human right, 1991–1992
privacy as, 74–75
Human Rights Act 1998 (UK), 245–246
Human Tissue Act 2004, 212–213
Human Tissue Authority, 205
human values, health research regulation and, 7
Hunt, Matthew, 315–316
Hurricane Katrina, distrust of government response in, 219–220
Hurst, S. A., 21–22, 25
Hutter, B., 161–162
hypothesis-driven trials, social value of, 54
Hyun, Insoo, 351
iden principle of identity, 384–386
identity
disclosure of research findings and, 229–231
human-technology embodiment and, 354–356
narrative as, health research participation and, 235–236
right to, 3501–49
IDx-DR AI diagnostic system, risk assessment and market approval, 258–259
IMDRF (International Medical Device Regulators Forum), software as medical device regulations and, 282–285
Immergut, E., 208
incidental research findings, 229–230
in neuroscience research, 309–310, 315
incorporativeness
in health research governance, 259–260
non-invasive prenatal testing and, 267–268
inclusive public engagement
data intensive health research and, 188–190
public expertise and, 251–253
incommensurability, proportionality and, 49–52
independent, interdisciplinary data access, 193–194
independent review boards, privacy and, 75–77
Indian Ocean tsunami, emergency healthcare and, 317–320
indirect benefit, in RCTs, 133
individuals and individualism
  autonomy guidelines in research ethics and, 29–30
data governance and, 59–60
group vulnerability and, 95–96
health research regulation and, 7, 14
individual vulnerability in research, 92–93
institutional decision-making and role of, 211
informational privacy, 75
data protection and, 75–77
risks to, 150
information technology, collaborative licensing, 144–145
informed consent
  alternate models of, 200–201
  basis for, 104–105
  in Big Data research, 123
  consent to contact policies and, 201–202
cultural factors in, 224n.23
data protection and, 67n.15
digital consent mechanisms and, 110
evolution of health research and, 103–104
fetishisation of, 181–182
group vulnerability and, 95–96
legal requirements for, 105–108
limitations of, 108–109
overview of, 105
privacy and, 75–77
proportionality and, 40
relational autonomy and, 30–31, 34–36
right of referral and, 108
solidarity in health research and, 59–61
trust and, 248–249
vulnerability and, 17–18, 20–22
waivers of, 109–200
written forms of, 108–109
infrastructural vulnerability, health research regulation and, 396, 23–24
inherent vulnerability, 33
innovative health research
  autologous mesenchymal stem cell intervention, 290–292
  clinical innovation in medical marketplace, 287–295
  collaborative licensing and, 144–145
  conflicts of interest in, 292–295
  disturbance of regulation from, 352–353
  emerging science and technology oversight and, 397–399
  enhancement innovations, 353–354
  ethical licensing and, 145–146
  government intervention and, 142–144
  market forces and, 140–141, 292–295
  medical device regulation and, 380–389
  national policy frameworks for genetics and, 377–378
  oversight and, 287–290, 292–295
  overuse of non-evidenced based therapies, 292–295
  patent regulation and, 139–147
  patent rights and, 142
  self-regulatory patent rights models and, 142–146
  Institute of Medicine (IOM, US), 124, 394–394
  Institutional Animal Care and Use Committee (IACUC), 360
  institutional capture, public engagement and, 108–109
  institutional review boards (IRBs)
    design and performance criticism of, 104
    purpose of, 177–178
    risk-benefit analyses and, 177–178
  single board (SRR), 200–201
  institutions
    accountability and risk aversion issues in, 211
    context of, 207–208
    decision-making body objectives in, 208–209
    decision-making body structure and composition, 209–211
    defined, 207–208
    design of, participatory governance and, 127–129
    health research regulation and, 14–15, 205–214
    influences on decision-making in, 208–213
    inter-institutional influences in, 213
    path dependencies and historical influences in, 211–213
    public vs. private duties in, 211
    solidarity of, health research and, 59–61
    trust in, 86–87
  instrumentality, public engagement and, 115–116
  intellectual property rights
    collaborative licensing and, 144–145
    patent regulation and, 140–141
    intended research findings, 229–230
    interconnectedness
      in health research regulation, 2
      learning healthcare systems and, 391–394
    inter-institutional design
      health research regulation and, 213
      learning healthcare systems and, 391–394
    Interministerial Commission for Research and Medicaments of Advanced Therapies (Argentina), 328–337
    internal validity, in RCTs, 328
    international
      Biethics Committee (UNESCO), 340–341
      Cancer Genome Consortium/25K Initiative, 193
      Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 203–205
      Covenant on Civil and Political Rights (UN), 105–106
      Ethical Guidelines for Health-related Research, 49–47
      Ethical Guidelines for Health-Related Research Involving Humans (CIOMS), 35–36, 46–47, 159, 190–200
      international health policies
        genetics research regulation and, 340–341
        human genome research, 352–353
      interpersonal solidarity, 58–59
      interpretive community, 210
      disclosure of research findings and, 236–238
interspecies biomedical research
chimeric organisms, 357–358
regulation of, 356–364
shifting regulatory boundaries in, 362–365
vulnerability issues, 363–364
interventions
autologous mesenchymal stem cell study, 290–292
clinical innovation oversight and, 287–290
component risk-benefit analysis, 135–136
risk identification in, 130–132
social value of, 49–51, 53–54
in vitro fertilization add-on procedures, 375–377
intrauterine culture, absence of effectiveness research on, 379
investigational therapeutics, global health emergencies and use of, 319
In Vitro Diagnostic Medical Devices Regulation (IVDR), 382–383, 386–389
in vitro fertilisation (IVF) add-on procedures in, 375–377
costs of, 375
culturing technological advances in, 368–370, 373–374
failure rate in, 375–377
14-day rule and, 361–366
non-evidence-based medicine in, 373–381
patient choice dynamics in, 380
special status principle in, 367–368
threshold of humanity principle in, 370–372
time pressures in, 374–377
Warnock Report findings and, 366–368
ipse principle of identity, 384–386
IUC, Rosario, 355–357
isomorphism
institutional decision-making and, 210
inter-institutional influences and, 213
issue characteristics, rare disease research, 61–62
Jackson, Emily, 373–378
Jacobs, Marie Andree, 304
Jasnow, Sheila, 396–397
Johnson, Summer, 218
justice
autonomy guidelines and, 27–29
as benefit sharing argument, 180–181, 194–196
human germline research, 352–355
informed consent and, 104–105
medical device failure and, 162–165
Kant, Immanuel, 78–79
Kaye, Jane, 103–111
Kerasidou, Angeliki, 14–15, 81–89
Kerridge, Ian, 287–295
Kieslich, Katharina, 14, 56–64
Kipnis, K., 396, 23–24
Klitzman, R., 203
Knight, D., 159–160
knowledge production
failure as tool for, 162–165
medical device failure and organisation of, 162–165
participatory government and forms of, 126–127
participatory health governance and, 285–286
risk-benefit analysis and, 132–134
Koop, Bert-Jaap, 273
Kummmats and Miller, 193
labelling approach, vulnerability research and, 20–22
ladder of public participation, 114, 116
Lane, Neal, 233–244
Lange, M. Meeke, 23–24
Langwick, Stacey, 304
laws and legislation
Argentinian health research regulation and, 330–331
data protection law, 243–245
fetishisation of consent and, 181–182
genomics research and, 356–361
group privacy protections and, 243–246
human embryos special status in, 367–368
informed consent and, 108–109
institutional decision-making and, 212–213
medical device regulation and, 388–389
physical integrity and identity in, 385–386
politics and barriers to, 223
privacy and, 242–245
public interest and, 67–70
shifting regulatory boundaries in animal research and, 362–363
traditional and non-conventional medicines and, 303–304
leadership support, participatory governance and, 127–129
learning healthcare systems
continuous learning and research-therapy divide in, 277–280
current and future trends in, 199
disclosure of research findings and, 231–234
minimal risk principle and, 199–200
patient engagement in, 124
regulatory science and, 391–394
risk identification in, 150–152
Learning Health Research Regulation System (LHRRS)
basics goals and features of, 399–400
ecosystem for, 397–399
learning healthcare systems and regulatory science and, 399–400
overview of, 1–10
proposals for, 5, 391–400
value and social values in, 349–356
legitimacy
medical device failure and, 163–164
of public engagement, 250–251
public interests and, 240–241
Lemley, Mark, 298–305
Leopoldina Society, 218, 220
licensing
collaborative licensing, 144–145
ethical licensing, 145–146
mixed licensing models, 143–144
non-exclusive research tool licensing, 142–143
reproductive medicine add-on services, 377–379
Index

temporary licensing, 165
in vitro fertilisation and, 374
lifecycle assessment, software as medical device and, 282–283
liability
advisory bodies and, 221
AI/ML device regulation and, 278
artificial intelligence and, 277–278
health policy advice and, 215–216
health research regulation and, 222–224
Liminal Spaces Project, 3
emerging science and technology oversight and, 397–399
limited disclosure of information, informed consent and, 107
Lipworth, Wendy, 287–295
Lloyd-Bostock, S., 161–162
local governance reviews
global health emergencies and, 309–320
inefficiencies with, 202
Long Term Plan (NHS), 271
low-and-middle income countries (LMIC)
benefit sharing in, 152–156
biotechnology regulation in, 324–325
global health emergencies in, 317–318
regulatory thresholds in, 357
trust in health research in, 81–82, 85–86
vulnerability of groups in, 93–95
Lowi, Theodore, 61–62
Lutra, F., 21–24
Lysaght, Tamar, 287–295
MacCormick, N., 208–209
machine learning
IDe-DR AI diagnostic system, 288–284
as medical device, 277–286
Mackenzie, Catriona, 32
maker movement, evolution of, 382–385
Managing Ethico-social, Technical and Administrative Issues in Data Access (METADAC, UK), 126
March, J., 209–211
Margulis, S. T., 242
market forces
autologous mesenchymal stem cell case, 290–292
clinical innovation and, 287–289
medical device regulation and, 382–383, 386–389
overuse of non-evidenced based therapies and, 292–295
patent regulation and, 140–141
in reproductive medicine, 375–377
Markingham, Dan, 21
May, William, 278
Mayo Clinic Biobank deliberation, 125–126
McLeod, Carolyn, 32, 34–35
Medical Assistance in Dying and When Antibiotics Fail (CCA), 219–220
medical devices. See also software as medical device (SaMD)
artificial intelligence/machine learning as, 277–286
clinical trials for, 279–281
current and future regulation concepts and perspectives, 382–390
expectations for, 160–162
failure of, 158–166
future challenges in regulation of, 389–390
knowledge base for, 162–165
market forces in regulation of, 386–389
participatory learning in regulatory governance of, 284–285
post-market surveillance of, 388–389
re-embedded risk and sociality and, 281–284
risk-based FDA classification of, 279
temporary licensing for, 165
Medical Devices Regulation (MDR, EU), 161, 386–389
Medicines and Healthcare Products Regulatory Agency (UK), 205, 377–379
Médicins sans Frontières, 132–133
Medina, José, 55–56
Megan’s Law, 285–286
mental health research, risk identification in, 130–132
Meslin, Eric M., 215–216
Mesmer, Anton, 220–221
METADAC (Managing Ethical, Sociotechnical and Administrative issues in Data Access), 197–198
metal-metal hips, expectations and failure involving, 150–152
MEURI (monitored emergency use of unregistered and experimental interventions) scheme, 319
Mexican General Health Law, 97
Mill, John Stuart, 107
Miller, Franklin, 233, 399–400
Millum, Joseph, 51–52
mimetic isomorphism, 213
minimal risk principle, health research regulation and, 199–200
mitochondrial replacement therapy (MRT) emergence of, 344–345
terminology and definitions of, 347
mixed licensing models, patent regulation and, 147–148
Mode 2 research, social values and, 47–49
Moffett, A., 376
monitoring, in health research governance, 259–260
moral agency
automated healthcare regulation and, 273–274
global health emergencies and, 321–322
human-technology embodiment and, 374–386
trust and, 85
trustworthy institutions and, 86–87
moral hazard, mixed licensing models and, 143–144
multi-agency research networks
learning healthcare systems and, 391–394
participatory health systems governance and, 126
multi-disciplinary efforts
institutional decision-making and, 210–211
learning healthcare systems and, 391–394
multilevel engagement strategies, participatory governance and, 128
Munroe, Megan, 287–295
Murtagh, M. J., 126
my data phenomenon, health research regulation and, 8–9
Index

Nabatchi, T., 254–255
Nagoya Protocol on Access and Benefit-Sharing, 149
narrative tools, research findings as, 235–236
National Academies of Sciences, Engineering and Medicine (NASEM, US), 259–260
National Academy of Science (NAS), chimera research guidelines, 359–362
National Administration of Drugs, Food and Medical Technology (NANMAT), 355–359
National Agency for Promotion of Science and Technology (ANPCTT, Argentina), 337–338
National Bioethics Advisory Commission (NBAC, US), 221–222
National Bioethics Advisory Commission (US), 151–152
National Commission for Agricultural Biotechnology (CONABIA) (Argentina), 334–335
National Consultative Committee on Ethics (France), 221
National Electronic Health Record System (NEHRS) (Australia), 128–130

Cambridge University Press
Index
More Information

© in this web service Cambridge University Press
www.cambridge.org
Index

organ donation/retention, regulations concerning, 212–213
Organisation for Economic Co-operation and
Development (OECD), data governance and,
190–191
orphan drugs research
societal reframing of, 63
solidarity in, 64–65
Oshana, Martina, 31
Ostrom, Elinor, 262–264
Ouye, P., 108–109
outputs of health research, 100
over-inclusive labelling, vulnerability in research and,
21–22
Oviedo Convention, 105–106, 340–341
pain relief protocols, vulnerability and, 19
Fang, T., 124
participants in health research
benefit sharing with, 154–156
disclosure of research findings and, 229–238
feedback to, 230
interests of, disclosure guidelines and, 214–215
in neuroscience research, 308
participatory governance. See also governance of research
clinical innovation oversight and, 289–290
enabling conditions for, 126–127
health research regulation and, 99–101, 121–129
health research systems, 123–126
institutional designs for, 127–129
international initiatives in, 124–125
participatory learning systems, regulatory governance and,
284–286
patent aggregation, 145
patent pledges, 145–146
patent pools, 144–145
patent rights and regulation
benefit sharing principle and, 150–151
ethical licensing, 145–146
government intervention and, 142–143
health research innovation and, 139–147
mixed licensing models, 143–144
non-exclusive research tool licensing, 142–143
as private regulation, 140–141
self-regulatory models for, 142–146
paternalism, vulnerability in research and, 22
path dependency, institutional decision-making and,
212–213
pathogenic vulnerability, 91
patient and public involvement (PPI). See also public
engagement
benefit treatment and, 54
consent and democratic approaches to, 122–123
disclosure of research findings and, 223–224
health research regulation and, 46, 48–49, 250–251
identity interests in, 397–399
increased demand for, 70–71
participatory governance in health research and,
121–129
patient-centered care, learning healthcare systems and,
391–394
Patient-Centered Outcomes Research Institute (PCORI,
US), 126–127
patient choice dynamics, reproductive medicine
regulation and, 580
patient health data
consent to contact policies and, 201–202
disclosure of research findings and role of, 233
research regulations for use of, 167–168
Patient Network for Advanced Therapies (APTA Network,
Argentina), 329
patterns of action, institutional decision-making and,
210–211
PAWORNt system (Riles), 284–285
perceptions of risk, risk-benefit analysis and, 134–135
performance of medical devices, research focus on,
162–165
permission to contact policies, 201–203
persuasive function, innovation oversight and, 292–295
permitted embryo concept, 329–340
personal data protection, privacy and,
75–77
Personal Genome Project, 103–104
pharmaceutical industry, solidarity-based research and,
62–63
placebo controls, evidence-based medicine and, 298–299
placental sampling, autonomy and consent to, 50–51
planned adaptations, research governance and, 264
policy formation in health research
Delphi policy study, 397–399
disclosure of research findings and, 229–238
evidence and evidence gathering and, 218–219
expert and advisory advice in, 215–224
future issues in, 222–224
international initiatives in, 124–125
governance of research
identity interests in, 92–93
individual vulnerability, 92–93
intersectoral biomedical research regulations and,
362–367
as private regulation, 140–141
learned and academic societies as experts for, 218–220
national genetics research frameworks for, 337–340
panaceas ideology in, 262–263
non-traditional medicine and, 209
patent regulation and, 140–141
policy advice experts and advisory committees and,
215–224
private regulation, 140–141
protection and, 97
public expertise and, 251–252
trustworthiness and, 248–249
vulnerabilities and power in, 90–98
policentricity. Big Data research and, 257–259
population groups
data on, 118–119
in health research regulation, 59–61
positive function, innovation oversight and, 292–295
Postan, Emily, 229–238
Index

posthumanism

enhancement innovations and, 383
identity and integrity issues and, 384–386
post-market surveillance, medical device regulation and, 388–389
post-trial obligations, benefit sharing and, 152–153
Potter, N. Nyquist, 84–85
poverty, vulnerability and, 92–93
Powell, W., 210
power
benefit sharing and role of, 154–156
definitions and analysis of, 90–91
group vulnerability and, 95–96
participatory governance and devolution of, 127–129
patent regulation and, 140–141
resource imbalance with, 126–127
trust and parity in, 85–86
vulnerabilities in health research politics and, 90–98
vulnerability and, 14–15
Prainsack, Barbara, 14, 56–64
precarity
in global crisis emergencies, 317–318
vulnerability and, 23–24
Precision Medicine Initiative (PMI, US), 103–104, 122–123
predictive influences, institutional decision-making in
health regulation and, 208
pregnancy
non-invasive prenatal testing and, 267–268
in vitro fertilisation risks in, 377
vulnerability of, 20–22, 33–34
preparedness principles, in global health emergency research, 322–323
preponderance theory, public interest and, 240
prescriptive influences, institutional decision-making in
health regulation and, 208
Prictor, Megan, 103–111
primary research, findings from, 229–230
primary stake development, human embryo research and, 367–370
principles-based regulation
AFIRM model and, 260–265
Big Data research, 257–259
development of, 169–172
health research regulation and, 167–176
limitations, 172–173
privacy
atomistic conception of, 241–243
in Big Data research, 123
data access governance and, 188–189
data protection law and, 243–245
defined, 241–243
duty of confidence and, 245–246
group privacy, 241–243
health research regulation and, 8–9, 14
as human right, 74–75
informed consent and, 75–77
legal protection of group privacy, 243–246
in modern context, 73
normativity of, 73–74
in personal data protection, 75–77

public interest and, 219–247
research governance and, 77–80
risk to violation of, 150
private sector healthcare
genomics research and, 336–341
learning healthcare systems and, 339–340
medical device regulation and, 386–389
misinformation about reproductive medicine and, 379
patents as, 140–141
reproductive medicine, 374, 377
procedural ambiguity, neuroscience research and, 310–312
procedural complementarity, 264
professional lay experts, participatory governance and, 117
Professional Standards Authority (PSA, UK), 504–502
progressive value, benefit analysis and, 53–54
proportionality
analytical complexities, 41–42
defined, 37–38
delimiting, 37–38
emerging science and technology oversight and,
clinical relevance and, 397–399
in global health emergency research, 322–323
of harms, 39–40
health research regulation and, 13–15
procedural approaches to, 42–45
of review, 39–40
social value and, 40–41
protected experimental use, patent regulation and, 141–142
protection, politics in health research and, 97, 141–142
protocol risks, vulnerability of participants and, 21
Public Accountability for Health-Related Research, CIOMS guidelines and, 37–49
public engagement. See also patient and public involvement; patient and public involvement (PPI)
anti-science politics and, 216–218
consultation and, 115–116
critique in, 112–113
empowerment and, 166
evaluation of, 119–120
forms of, 113–116
global health emergencies and, 319–320
health research regulation and, 7, 99–101
human genomics research and, 354–355
inclusive approach to, 118–119
layers of, 114–115
narrative of findings as tool for, 235–236
overview, 112
participatory learning in regulatory governance and, 284–285
public expertise mobilisation and, 248–256
representation and inclusiveness issues in, 251–253
trust and legitimacy challenges in, 250–253
trustworthiness of research governance and, 248–249
types of public in, 117
public expertise, mobilisation of
deliberation and, 253–255
health research regulation and, 14
public funding, patent regulation and, 141–142
Public Health England, Value of Vaccines campaign, 115
public interest
Index

automated healthcare and balancing of, 267–268
CIOMS Public Engagement guidelines and, 47–49
common interests and, 240–241
contested concepts of, 65–66
data accessibility and, 70–71
data protection law and, 243–245
decision-making in, 211
deliberative public engagement and, 252–255
health research regulation and, 13–15
holistic concepts of, 71–72
as legal device, 67–70
privacy and, 78, 239–247
trust and legitimacy challenges in, 250–251

public-private models
genomics research regulation, 336–341
learning healthcare systems and, 391–394
public reason, public interest and, 240–241
pure public, classification of, 187
Quality-Adjusted Life Years, proportionality and social value, 40–41
Quality-Adjusted Time Without Symptoms and Toxicity (Q-TWIST) test, 158
Quality Management System (QMS), AI/ML medical device regulation and, 283–284
quandary ethics, medical device failure and, 163

Raah, C. D., 242–243
Rahmzadeh, V., 205
Rai, R., 376–377
randomised clinical trials (RCTs)
design in reproductive medicine for, 374–377
evidence-based medicine and, 298–299
global health emergency research and challenges of, 318–320
reproductive medicine and lack of, 373–374
risk-benefit analysis and, 132–134
range of sensitivities, privacy and, 79
tare disease research, solidarity in, 66–67
Rawls, John, 49, 78–79, 240n.7
Raz, Joseph, 31
REACH platform, 284–285
real-time responsiveness, global health emergencies and, 320–322
reasonable availability model, benefit sharing and, 152–153
reasonableness and reason-giving, diversity theory and, 255–257
reasonable risk, risk-benefit analysis and, 156–157
redundancy, Big Data research and, 257–259
Reed, Chris, 277–278
reflectivity, in health research governance, 259–260
refusal, informed consent and right of, 108
regenerative medicine
advanced therapies in, 124
Argentinian governance of research in, 325–326
regulation and oversight of, 359–362
vulnerability issues in, 363–364
registrant risk assessment scale (RRAS), 285–286
regulatory committees, institutional context for, 205
regulatory/governance approach (RGA)
AI/ML medical devices and, 281–284
to health research, 167–168
participatory learning systems and, 284–286
regulatory lapse, emerging technologies and, 167–168
regulatory regimes
clinical care vs., 6
clinical innovation oversight and, 289
inefficiencies in committees, 201–202
innovation oversight and, 292–295
medical devices and changes in, 279–281
recent challenges for, 4–5
regulatory responsibility
automated healthcare regulation and, 273–274
human germline research, 350–352
regulatory science, learning healthcare systems and, 391–394
reproductive autonomy
informed consent and, 54–56
participatory governance and, 127–129
principles of, 20–23
vulnerability and, 33–34
reliability, trustworthiness and, 88n.45
Reliable Replacement Warhead (RRW) program, 285–286
reliance, trust in global health research and, 83–86
representation and representativeness
group vulnerability and, 95–96
participatory governance and, 126–127
in public engagement, 251–253
representative diversity, 252–253
reproductive autonomy, non-invasive prenatal testing and, 267–268
reproductive immunology
lack of research and regulation of, 375–377
off-label use of, 377–379
reproductive medicine.
See also cloning
add-on services regulation in, 377–379
alternative treatments in, 175–177
context in research on, 348–350
disclosure guidance in, 232, 227–228
evolution of regulatory framework for, 366–368
14-day rule and, 365–372
global regulations and policies and, 352, 354–355
human gene editing and, 267–268, 336–341
innovation oversight in, 292–295
non-evidence-based medicine and, 326–328
patient choice dynamics in, 380
pre-implantation genetic diagnosis and, 336–341
risks of add-ons in, 380–381
threshold of humanity principle in, 370–372
researchers ethical capacities, global health emergencies and, 322–323
research ethics boards (REBs)
purpose of, 177–178
risk-benefit analysis and, 177–178
research ethics committees (RECs), 46
design and performance criticism of, 180–181
fetishisation of consent and, 181–182
future directions for, 154–155
innovation oversight and, 292–295
neuroscience research and, 304
representative diversity, 252–253
relational autonomy
informed consent and, 54–56
participatory governance and, 127–129
principles of, 20–23
vulnerability and, 33–34
real-time responsiveness, global health emergencies and, 320–322
reasonable availability model, benefit sharing and, 152–153
reasonableness and reason-giving, diversity theory and, 255–257
reasonable risk, risk-benefit analysis and, 156–157
redundancy, Big Data research and, 257–259
Reed, Chris, 277–278
reflectivity, in health research governance, 259–260
refusal, informed consent and right of, 108
regenerative medicine
advanced therapies in, 124
Argentinian governance of research in, 325–326
regulation and oversight of, 359–362
vulnerability issues in, 363–364
registrant risk assessment scale (RRAS), 285–286
regulatory committees, institutional context for, 205
regulatory/governance approach (RGA)
AI/ML medical devices and, 281–284
to health research, 167–168
participatory learning systems and, 284–286
regulatory lapse, emerging technologies and, 167–168
regulatory regimes
clinical care vs., 6
clinical innovation oversight and, 289
inefficiencies in committees, 201–202
innovation oversight and, 292–295
medical devices and changes in, 279–281
recent challenges for, 4–5
regulatory responsibility
automated healthcare regulation and, 273–274
human germline research, 350–352
regulatory science, learning healthcare systems and, 391–394
reproductive autonomy, non-invasive prenatal testing and, 267–268
reproductive immunology
lack of research and regulation of, 375–377
off-label use of, 377–379
reproductive medicine.
See also cloning
add-on services regulation in, 377–379
alternative treatments in, 175–177
context in research on, 348–350
disclosure guidance in, 232, 227–228
evolution of regulatory framework for, 366–368
14-day rule and, 365–372
global regulations and policies and, 352, 354–355
human gene editing and, 267–268, 336–341
innovation oversight in, 292–295
non-evidence-based medicine and, 326–328
patient choice dynamics in, 380
pre-implantation genetic diagnosis and, 336–341
risks of add-ons in, 380–381
threshold of humanity principle in, 370–372
researchers ethical capacities, global health emergencies and, 322–323
research ethics boards (REBs)
purpose of, 177–178
risk-benefit analysis and, 177–178
research ethics committees (RECs), 46
design and performance criticism of, 180–181
fetishisation of consent and, 181–182
future directions for, 154–155
innovation oversight and, 292–295
neuroscience research and, 304

© in this web service Cambridge University Press
www.cambridge.org
research ethics committees (RECs) (cont.)
purpose of, 177–178
regulatory role of, 178–180
risk-benefit analysis and, 157–158
social value and, 52–53
standardisation of procedures for, 182–184

Research Involving People Living in Developing Countries: Position Statement and Guidance Notes for Applicants (Wellcome Trust), 151
research-therapy divide, continuous learning systems and, 277–286
Resnik, D. B., 12
resource/power imbalance, participatory governance and, 126–127
respect for persons, autonomy guidelines and, 27–29
responsiveness, in health research governance, 259–260
review, proportionality of, 39–40
revisionist, scientific claims and, 49
Richardson, Megan, 246
Richert, Lucas, 303–304
Rid, A., 49–52, 71–72
The Right to Privacy (Richardson), 246
right to try principle
clinical innovation and, 288–289
misinformation about reproductive medicine and, 279
rigorous justification, proportionality and, 43
Rijke, J., 261
Riles, Anneline, 284–285
Rip, A., 159–160
risk
defined, 170
failure in health research and, 158–166
in health research governance, 259–260
identification of, 150–152
institutional aversion to, 211
medical device classification based on, 279
re-embedded risk in medical devices, 281–284
of reproductive add-on treatments, 380–381
SaMD risk characterization framework, 282–283
social value of research and, 199–200
risk-benefit analysis
benefits identification, 152–154
disclosure of research findings and, 230–231
first-order proportionality and, 37–38
in health research regulation, 250–253
health research regulation and, 14
medical devices and, 160–162
methodologies for, 155–157
procedural issues, 157–158
public interest and role of, 250–251
quantification of, 154–155
risk identification in, 110–112
risk object designation
AI/ML algorithm and, 279–280
medical device regulation and, 386–389
re-embedded risk and sociality and, 281–284
regulatory governance and, 285–286
software as medical device, 277–278
Robertson, John, 178
Roche, Ellen, 21

Index

Rogers, Wendy A., 15, 17–26
Rose v. Secretary of State for Health, 385–386
Rowe, G., 114
Royal Academy of Sciences, 218
Royal Society (UK), 218, 220
Royal Society of Canada, 219–220
Rudge, Chris, 257–259
rules-based approaches (RBAs)
amplified healthcare regulation and, 270–271
development of, 189–172
health research regulation and, 167–176
limitations, 172–173
R v. (Source Informatics) v. Department of Health, 246
R (WXY and Z) v. Secretary of State for Health (2015), 245–246
safety
expectations and failure involving, 160–162
of traditional medicine, research on, 299–301
Salter, B., 288–289
Schaefier, Gerald Owen, 13–14
Schulz, S., 112–113, 117
science and technology studies (STS)
health research regulation in, 49–49
public engagement in, 112–113
traditional and non-conventional medicines and, 503–504
scientific truth
health policy and, 217
negotiation and agreement over, 49
scientific uncertainty, risk-benefit analysis and, 154–155
secondary research findings from, 229–230
institutional decision-making on, 212–213
regulation of, 199–200
second-order proportionality, defined, 37–38
security, data access governance and, 188–189
self-development, automated healthcare regulation and, 27–28
self-narrative, health research participation and, 235–236
self-regarding attitudes, relational autonomy and, 32
self-trust, relational autonomy, 32
semi-autonomous consent, 110
sequencing, in health research regulation, 295–296
Serwadda, D., 158–169
Seft, Navah, 99–103, 167–176
Sherkow, Jacob, 141–142
Shreve, N., 376
Simms, Kaidr, 148–157
single institutional review board (sIRB), proposals for, 200–201
situational vulnerability, 33
slippery slope ideology, human germline research and, 549–550
social conditions
adaptive governance and, 262–263
Big Data research and, 123
relational autonomy and, 31
social learning, adaptive governance and, 263–265
social practices of healing, 209–210

© in this web service Cambridge University Press
www.cambridge.org
social value
application of, 52–55
automated health regulation and, 270–271
benefit analysis and, 53–54
benefit evaluation and, 54
benefit treatment and, 54
decision-making and, 54
of global health emergency research, 317–318
global health emergency research and, 318–320
health research regulation and, 14, 46–55, 199–200, 268
meaning of, 49–51
proportionality and, 40–41
re-embedded risk in medical devices and, 281–284
scholarly debate on, 51–52
in sociology of science, 47–49
solidarity as, 58–59
values and, 49–51, 394–396
sociology of science
neuroscience research and, 306–307
social value in, 47–49
therapeutic interactions research, 299
soft law
on benefit sharing, 152
genomics research and, 316–341
software as medical device (SaMD)
IDe-X AI diagnostic system, 278–281
regulation of, 277–278
risk characterization framework, 282–283
solidarity
applicability and adjustments in HHR and, 58–59
automated health regulation and, 270–271
as benefit sharing argument, 150–151
as community and system value, 58–59
in health research regulation, 14, 56–64
meaning of, 56–58
rare diseases and orphan drugs research and, 61–63
Somatic Gene and Engineered Cell Therapies (CACA), 219–220
somatic gene therapy, regulation of, 316–341
somatic/germline distinction, human germline research and, 350
Sorauf, F. J., 240
Sorbic, Annie, 14, 65–72
Spanish Agency for Medicaments, Argentinian collaboration with, 319
special vulnerability paradigm, 19–20
health research ethics and, 19–20
stakeholder engagement
automated health regulation and, 268–269
Big Data research and, 257–259
data protections and, 183
failure in health research and, 158–159
independent, interdisciplinary data access and, 193–194
marginalisation in vaginal mesh failure and, 162–165
principles-based approaches and, 171–172
value-driving paradigm for, 394–396
state decision, institutional decision-making and, 212–213
Stark, Laura, 178–179
stem cell research
Argentinian regulation of, 326–328
autologous mesenchymal stem cell case, 290–292
regulation and oversight of, 359–362
shifting regulatory boundaries in, 362–363
vulnerability issues in regulation of, 363–364
Stem Cell Research Oversight (SCRO) committees, interspecies research oversight, 360
stereotyping, in vulnerability research, 20–22
stewardship
ethics in health research and, 182–184
health research regulation and, 268, 397–399
participatory health research governance and, 124
Stewart, Cameron, 287–295
Stigl, J., 112
Stoljar, Natalie, 13, 27–36
study design and size, RCTs and, 133
subjectivity, public engagement and, 113–116
substantial equivalence principle, medical device risk and, 271
supplementary guidance, health research regulation, 173–175
surrogate licensing, patent regulation and, 141–142
systemic oversight
AFIRRM model and, 262
Big Data research and, 259–260
context in, 262
structures of governance and, 263
systems approach
participatory governance in health research and, 123–126
to research regulation, 4–5
system value, solidarity as, 58–59
Taylor, Mark, 68–69, 71–72, 219–247
technology
Argentinian regulation of, 324–325
automated healthcare, 266–274
automated healthcare regulation and, 270–271
collaborative licensing and, 144–145
disruption of regulation from, 382–383
failure of, 158–166
health research regulation and, 199–200, 198–199
informed consent and evolution of, 103–104
non-exclusive research tool licensing and, 142–143
patent rights and innovation in, 141
regulatory lapse and, 167–168
regulatory responsibility and, 271–274
Tello, J. E., 123–124
temporary licensing, for medical devices, 165
ten Have, H., 91
Ter Muelen, Rudo, 58–59
Testfri, Henri, 218
theory-practice gaps, rule-based and practice-based health regulation and, 172–173
therapeutic misconception, benefit sharing and, 154–156
third-party risks, identification of, 110–112
Thompson, J., 127
threshold of humanity principle
enhancement innovations and, 383
human embryo research and, 370–372
Tietjens, Diana, 31
Index

420

United Kingdom
data protection law in, 243–245
duty of confidence and privacy protection in,
245–246
evidence-informed health policy in, 266–268
top-down public engagement, 248
utility theory, public interest and, 240

vaginal mesh
economics of clinical guidelines for, 301–312
values
economics of clinical guidelines for, 301–312
economics of clinical guidelines for, 301–312
validity in health research
disclosure of findings criteria and, 231, 236–238
economics of clinical guidelines for, 301–312
validity in health research
disclosure of findings criteria and, 231, 236–238
external vs. internal validity, 173
values
economics of clinical guidelines for, 301–312

vaginal mesh
economics of clinical guidelines for, 301–312

values
economics of clinical guidelines for, 301–312

validity in health research
disclosure of findings criteria and, 231, 236–238


UK Biobank, 194–195

vulnerability
ambiguity in HRR and, 19–20
benefit sharing and, 154–156
definition and analysis of, 23–24, 90–91
global health emergency guidelines and, 316–317
of groups, 92–93
health research regulation and, 13
individuals’ vulnerability, 92–93
interspecies biomedical research and realignment of,
316–317
labelling approaches to research on, 20–22
layers of, 316, 23–24
politics of health research and, 90–98
power and, 14–15
in rare disease research, 62
relational autonomy and, 33–34
in research ethics guidelines, 17–18
risk assessment and, 199–200
taxonomy, 24
trust and, 83–85
universal capacity and, 24–25

Wainwright, Steven, 313
Waldby, Catherine, 257–295
Warnock Committee of Inquiry into Human Fertilisation and Embryology, report by, 366–368
Warren, Mark, 251–252
Weijer, Charles, 46–47, 96
welfare state, enforceability of solidarity and, 58–59
Wellcome Trust
on benefit sharing, 151
Blueprint for Dynamic Oversight of Emerging Science and Technologies, 397–399
public interest and, 68–69
Understanding Patient Data initiative, 70–71
Wendler, D., 49–52
Wenner, Danielle, 51–52
Wertheimer, A., 52
Western Herbalism, 299–301
Whitton, Tess, 239–247

WHO Guidance for Managing Ethical Issues in Infectious Disease Outbreaks, 173–175
Wiersma, Miriam, 287–295
Wilcox, D., 115–116
Wills, R., 119–120
Wilsdon, J., 119–120
Working Group on Disaster Research Ethics (WGDRE), 317–318
World Health Organization (WHO)
bioethics advisory committees and, 221
CIOMS collaboration with, 46–47, 59–61
global health emergency guidelines and, 320–322
Good Clinical Practice, 152
health practices guidelines, 173–175
health systems framework, 123–124
traditional medicine and, 296–301
World Medical Association (WMA), 103–104
Wright, E. O., 124–125, 127–129
Wrigley, A., 91, 97
written assessments, risk-benefit analysis and, 137–138
Wynne, B., 112–113
Yishai, Y., 125
Zhan, Mei, 303–304
Zhang, John, 346, 353
Zita West fertility clinic blog, 376–377